99 related articles for article (PubMed ID: 19122334)
1. Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure.
Tsujimoto M; Dan Y; Hirata S; Ohtani H; Sawada Y
Drug Metab Pharmacokinet; 2008; 23(6):406-11. PubMed ID: 19122334
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects.
Tsujimoto M; Hirata S; Dan Y; Ohtani H; Sawada Y
Drug Metab Pharmacokinet; 2006 Apr; 21(2):165-9. PubMed ID: 16702737
[TBL] [Abstract][Full Text] [Related]
3. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
[TBL] [Abstract][Full Text] [Related]
4. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients.
Boivin AA; Cardinal H; Barama A; Naud J; Pichette V; Hébert MJ; Roger M
Drug Metab Pharmacokinet; 2013; 28(3):274-7. PubMed ID: 23149872
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).
Letschert K; Keppler D; König J
Pharmacogenetics; 2004 Jul; 14(7):441-52. PubMed ID: 15226676
[TBL] [Abstract][Full Text] [Related]
6. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Hamada A; Sissung T; Price DK; Danesi R; Chau CH; Sharifi N; Venzon D; Maeda K; Nagao K; Sparreboom A; Mitsuya H; Dahut WL; Figg WD
Clin Cancer Res; 2008 Jun; 14(11):3312-8. PubMed ID: 18519758
[TBL] [Abstract][Full Text] [Related]
7. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.
Geng F; Jiao Z; Dao YJ; Qiu XY; Ding JJ; Shi XJ; Li ZD; Zhong MK
Clin Chim Acta; 2012 Apr; 413(7-8):683-90. PubMed ID: 22227166
[TBL] [Abstract][Full Text] [Related]
8. Extreme differences in SLCO1B3 functional polymorphisms in Roma and Hungarian populations.
Nagy A; Szalai R; Magyari L; Bene J; Toth K; Melegh B
Environ Toxicol Pharmacol; 2015 May; 39(3):1246-51. PubMed ID: 26005078
[TBL] [Abstract][Full Text] [Related]
9. Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
Laitinen A; Niemi M
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):9-13. PubMed ID: 20560925
[TBL] [Abstract][Full Text] [Related]
10. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects.
Woo HI; Kim SR; Huh W; Ko JW; Lee SY
Drug Des Devel Ther; 2017; 11():1135-1146. PubMed ID: 28435225
[TBL] [Abstract][Full Text] [Related]
11. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
[TBL] [Abstract][Full Text] [Related]
12. ABCB1 and SLCO1B3 Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population.
Tounsi N; Trabelsi I; Kerkeni E; Grissa MH; Fredj N; Sekma A; Mzali M; Hellara I; Monastiri K; Douki W; Nouira S
Pharmacology; 2017; 99(5-6):250-258. PubMed ID: 28208135
[TBL] [Abstract][Full Text] [Related]
13. [Advances in the study of organic anion transporting polypeptide 1B3].
Li X; Li Y
Yao Xue Xue Bao; 2011 Nov; 46(11):1279-85. PubMed ID: 22260016
[TBL] [Abstract][Full Text] [Related]
14. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
15. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging.
Nassif A; Jia J; Keiser M; Oswald S; Modess C; Nagel S; Weitschies W; Hosten N; Siegmund W; Kühn JP
Radiology; 2012 Sep; 264(3):741-50. PubMed ID: 22771883
[TBL] [Abstract][Full Text] [Related]
16. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
17. Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population.
Chae YJ; Lee KR; Noh CK; Chong S; Kim DD; Shim CK; Chung SJ
J Pharm Sci; 2012 Mar; 101(3):1302-13. PubMed ID: 22147445
[TBL] [Abstract][Full Text] [Related]
18. Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells.
Taub ME; Mease K; Sane RS; Watson CA; Chen L; Ellens H; Hirakawa B; Reyner EL; Jani M; Lee CA
Drug Metab Dispos; 2011 Nov; 39(11):2093-102. PubMed ID: 21849517
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
20. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Franke RM; Baker SD; Mathijssen RH; Schuetz EG; Sparreboom A
Clin Pharmacol Ther; 2008 Dec; 84(6):704-9. PubMed ID: 18509328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
